Scancell Holdings PLC (SCLP)
Industry Biotechnology
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell
9.60p
Buy
10.20p
0.00p (+0.00%)
Prices updated at 12 Dec 2025, 17:07 GMT
| Prices minimum 15 mins delay
Prices in GBX
Scancell Holdings PLC is a biopharmaceutical company focused on the cancer therapeutics market. The company's principal activity consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Biotechnology
Chairman
Ms. Susan Elizabeth Clement-Davies
CEO
Dr. Philip John L'Huillier
Most recent earnings
30 Apr 2025
Fiscal year end
30 Apr 2025
Employees
61
Head office
Sanders Road
Oxford
United Kingdom
OX4 4GD
Key personnel
Owner name | Salary |
|---|---|
Ms. Susan Elizabeth Clement-Davies Non-Executive Director, Deputy Chairman | - |
Mr. Martin Henry Diggle Non-Executive Director | - |
Mr. Sath Nirmalananthan Executive Director, Chief Financial Officer and Company Secretary | - |
Dr. Philip John L'Huillier Executive Director, Chief Executive Officer | - |
Top 5 shareholders
Owner name | No. of shares |
|---|---|
| AXA Investment Managers UK Ltd | 12,127,152 |
| UTM IM GBP AXA Framlington Biotech | 12,127,152 |
| Calculus Capital Limited | 2,531,034 |
| AXA Investment Managers Paris S.A. | 562,904 |
| AXA IM Wave Biotech Fund | 562,904 |
Director dealings
Date | Action |
|---|---|
| 12 Sep 2025 | Purchase |
| 07 Aug 2025 | Purchase |
| 01 Aug 2025 | Purchase |
| 30 Jul 2025 | Purchase |
| 20 May 2025 | Purchase |
| 16 May 2025 | Purchase |
| 15 May 2025 | Purchase |
Please note that past performance is not a reliable indicator of future returns.
